SCHEMBL7567552

SCHEMBL7567552

Cc1cccc2c1N(CC(=O)N1CC3CCC(CC3)C1)C(=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)N=C2c1ccccc1F

nearest known ligand 0.64

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 15/20 0.64
CCKAR P32238 4/20 0.64
SCN9A Q15858 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7567556 1.00 CCKBR (0.64) CCKBRCCKARSCN9A
SCHEMBL7544443 0.88 CCKBR (0.70) CCKBRCCKARSCN9A
SCHEMBL7544439 0.88 CCKBR (0.70) CCKBRCCKARSCN9A
SCHEMBL7552581 0.85 CCKBR (0.67) CCKBRCCKAR
SCHEMBL7552588 0.85 CCKBR (0.67) CCKBRCCKAR
SCHEMBL7575959 0.85 CCKBR (0.62) CCKBRCCKARSCN9A
SCHEMBL7552308 0.83 CCKBR (0.60) CCKBRCCKARSCN9A
SCHEMBL7552304 0.83 CCKBR (0.60) CCKBRCCKARSCN9A
SCHEMBL7543458 0.82 CCKBR (0.62) CCKBRCCKARSCN9A
SCHEMBL7543454 0.82 CCKBR (0.62) CCKBRCCKARSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020002163-A1 1,4-benzodiazepinones and their uses as CCK antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 US disclosed
US-6291452-B1 CHOLECYSTOKININ ANTAGONISTS. FUJISAWA PHARMACETICAL CO., LTD. (JP) 2001-09-18 US disclosed
EP-0934282-A1 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-08-11 EP disclosed
WO-1998015535-A1 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002163-A1 1,4-benzodiazepinones and their uses as CCK antagonists CCKAR, CCKBR, GABRA4 CCKBR 2/4885CCKAR 1/4885SCN9A 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.